# Global Wearables in Pharma & Biotech Market by Product, Therapy, Application, and End User - Forecast to 2031 | AI and Remote Monitoring Drive 20.2% CAGR to $9.97 Billion

- Published: 2026-11-17
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/global-wearables-in-pharma-biotech-market-by-product-therapy-application-and-end-user-fore/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

*Capitalize on RPM, CGMs and biosensors; target Asia Pacific growth, pharma clinical trials and home-based care through reimbursement, partnerships and advanced analytics.*

Dublin, Nov. 17, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.researchandmarkets.com/reports/6234836/wearables-in-pharma-and-biotech-market-product?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=jtfgzt&amp;utm_campaign=2404926+-+Global+Wearables+in+Pharma+%26+Biotech+Market+by+Product%2c+Therapy%2c+Application%2c+and+End+User+-+Forecast+to+2031+%7c+AI+and+Remote+Monitoring+Drive+20.2%25+CAGR+to+%249.97+Billion&amp;utm_exec=clshmsai" rel="nofollow">"Wearables in Pharma & Biotech Market by Product, Therapy, Application, End User - Global Forecasts to 2031"</a> has been added to **ResearchAndMarkets.com's** offering.

The wearables in pharma & biotech market is projected to grow from USD 3.98 billion in 2026 to USD 9.97 billion by 2031, registering a CAGR of 20.2%. Market expansion is being supported by advances in biosensors, device miniaturization, digitization, remote patient monitoring, and digital care solutions. Improved sensor accuracy and multi-parameter monitoring are also enabling wearable devices to capture clinically significant endpoints for drug development, therapeutic studies, and drug safety assessment.

Expanding digital connectivity is accelerating the integration of wearable-generated data with cloud platforms and healthcare systems. According to the International Telecommunication Union, more than 5.4 billion people worldwide used the internet in 2023. Large-scale biomedical initiatives are also demonstrating the value of wearable technologies. The All of Us Research Program has enrolled more than 500,000 participants, with some contributing activity, heart rate, and sleep data. Similarly, the UK Biobank has collected wearable data from more than 100,000 individuals.

Supportive reimbursement policies are strengthening adoption among healthcare providers. In the US, the Centers for Medicare & Medicaid Services recorded substantial growth in reimbursement claims for remote physiological monitoring services after its 2022 policy expansion. This trend highlights the increasing use of wearable-derived data in clinical care and chronic disease monitoring.

**Continuous Glucose Monitors Lead the Product Segment**

The product market includes smartwatches, fitness bands, smart rings, continuous glucose monitors (CGMs), patches, wearable injectors, and other devices. CGMs are expected to account for the largest market share, supported by clinical recommendations, broader patient eligibility, reimbursement coverage, and compatibility with advanced diabetes management systems.

The American Diabetes Association's 2024 Standards of Care recommends CGM use across a broad population of patients with diabetes. Adoption is also benefiting from National Health Service reimbursement programs and Food and Drug Administration approvals for interoperable CGMs used with insulin delivery systems. With the ability to generate up to 288 glucose readings per day, these devices provide extensive data for treatment decisions and long-term disease management.

**Pharmaceutical and Biotech Companies Remain the Largest End Users**

Pharmaceutical and biotech companies accounted for the largest end-user share in 2025. Wearable technologies are increasingly incorporated into clinical trials to support continuous, decentralized, and objective data collection. According to the Tufts Center for the Study of Drug Development, current clinical trial protocols include more than 20 endpoints on average, increasing demand for scalable data capture technologies.

Wearables can support drug discovery, Phase II, Phase III, and Phase IV clinical trials, medication adherence, behavioral support, chronic disease monitoring, and personalized and preventive digital therapeutics. Their ability to collect data outside conventional clinical settings makes them increasingly valuable for complex study designs and patient-centric research.

**Asia Pacific Poised for the Highest Growth**

Asia Pacific is expected to record the highest growth rate during the forecast period. Key factors include improving digital health infrastructure, increasing clinical research activity, rising internet penetration, and a substantial population requiring better access to continuous monitoring. Internet penetration across Asia Pacific has surpassed approximately 66% to 70% in recent years, according to the International Telecommunication Union.

China and India are also becoming major clinical trial hubs, encouraging the use of wearable technologies to improve trial efficiency, participant monitoring, and data quality. The region's disease burden and continued investment in connected healthcare are expected to create significant opportunities for wearable device manufacturers, pharmaceutical companies, and digital health providers.

**Competitive Landscape and Research Coverage**

Key participants in the wearables in pharma & biotech market include Abbott, Dexcom, Inc., Masimo, BD, and Medtronic. The report assesses company profiles, market shares, service offerings, product launches, partnerships, agreements, mergers & acquisitions, investments, and growth strategies. It also evaluates emerging startups and competitive developments across the market ecosystem.

The report segments the market by product, therapeutic area, application, end user, and region. Therapeutic areas include cardiovascular disease, oncology, diabetes, mental health & behavioral health, respiratory disorders, neurology, musculoskeletal disorders and pain management, women's health & reproductive health, lifestyle & wellness improvement, and other diseases. Regional coverage includes North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

**Key Market Factors**

-   **Growth drivers:** Adoption of value-based and patient-centric healthcare, increasing prevalence of chronic diseases, healthcare digitization, and expansion of telehealth services.
-   **Market restraints:** High implementation and integration costs, data privacy risks, and cybersecurity concerns.
-   **Growth opportunities:** Expansion of remote patient monitoring, home-based care, advanced analytics, and personalized healthcare.
-   **Industry challenges:** Interoperability limitations, integration with existing healthcare IT systems, low patient adoption, and digital literacy barriers.

Primary research participants included 60% Tier 1 companies, 30% Tier 2 companies, and 10% Tier 3 companies. Respondents comprised 30% C-level executives, 50% Director-level professionals, and 20% other participants. By region, representation included North America at 45%, Europe at 20%, Asia Pacific at 25%, and the Rest of the World at 10%.

The report provides market participants with revenue estimates, segment-level analysis, competitive intelligence, technology trends, and insights into market drivers, restraints, opportunities, and challenges. These findings can support product development, market diversification, investment planning, competitive positioning, and go-to-market strategies in the rapidly expanding wearables in pharma & biotech market.

**Key Attributes:**  
  

| Report Attribute | Details |
| --- | --- |
| No. of Pages | 401 |
| Forecast Period | 2026 - 2031 |
| Estimated Market Value (USD) in 2026 | $3.98 Billion |
| Forecasted Market Value (USD) by 2031 | $9.97 Billion |
| Compound Annual Growth Rate | 20.2% |
| Regions Covered | Global |

  
**Key Topics Covered:**  
  
**1 Introduction**  
1.1 Study Objectives  
1.2 Market Definition  
1.3 Study Scope  
1.3.1 Market Segmentation and Regional Scope  
1.3.2 Inclusions and Exclusions  
1.3.3 Years Considered  
1.4 Currency Considered  
1.5 Unit Considered  
1.6 Stakeholders  
  
**2 Executive Summary**  
2.1 Key Insights and Market Highlights  
2.2 Key Market Participants: Mapping of Strategic Developments  
2.3 Disruptive Trends Shaping Wearables in Pharma & Biotech Market  
2.4 High-Growth Segments  
2.5 Regional Snapshot: Market Size, Growth Rate, and Forecast  
  
**3 Premium Insights**  
3.1 Attractive Opportunities for Wearables in Pharma & Biotech Market  
3.2 North America Wearables in Pharma & Biotech Market, by End-user and Country  
3.3 Wearables in Pharma & Biotech Market, by Country  
  
**4 Market Overview**  
4.1 Introduction  
4.2 Market Dynamics  
4.2.1 Drivers  
4.2.1.1 Shift Toward Value-based and Patient-Centric Healthcare Models  
4.2.1.2 Prevalence of Chronic Diseases Requiring Continuous Patient Monitoring  
4.2.1.3 Rapid Digitalization of Healthcare and Expansion of Telehealth Services  
4.2.2 Restraints  
4.2.2.1 High Implementation and Integration Costs  
4.2.2.2 Data Privacy and Cybersecurity Concerns  
4.2.3 Opportunities  
4.2.3.1 Expansion of Remote Patient Monitoring and Home-based Care Models  
4.2.3.2 Integration of Advanced Analytics and Personalized Healthcare  
4.2.4 Challenges  
4.2.4.1 Limited Interoperability with Existing Healthcare IT Systems  
4.2.4.2 Low Patient Adoption and Digital Literacy Barriers  
4.3 Unmet Needs and White Spaces  
4.4 Interconnected Markets and Cross-Sector Opportunities  
4.5 Strategic Moves by Tier-1/2/3 Players  
  
**5 Industry Trends**  
5.1 Porter's Five Forces Analysis  
5.1.1 Bargaining Power of Suppliers (Moderate)  
5.1.2 Bargaining Power of Buyers (Moderate to High)  
5.1.3 Threat of Substitutes (Low to Moderate)  
5.1.4 Threat of New Entrants (Moderate)  
5.1.5 Intensity of Competitive Rivalry (High)  
5.2 Macroeconomic Indicators  
5.2.1 GDP Trends and Forecast  
5.2.2 Trends in Global Healthcare IT Industry  
5.3 Supply Chain Analysis  
5.4 Ecosystem Analysis  
5.5 Pricing Analysis  
5.5.1 Indicative Pricing Analysis of Key Players, by Product, 2025  
5.5.2 Indicative Pricing Analysis, by Region, 2025  
5.6 Trade Analysis  
5.6.1 Import Data (HS Code 9018)  
5.6.2 Export Data (HS Code 9018)  
5.7 Key Conferences and Events, 2026-2027  
5.8 Trends/Disruptions Impacting Customer Business  
5.9 Investment and Funding Scenario  
5.10 Case Study Analysis  
5.11 Impact of 2025 US Tariff  
5.11.1 Key Tariff Rates  
5.11.2 Price Impact Analysis  
5.11.3 Impact on Countries/Regions  
5.11.3.1 US  
5.11.3.2 Europe  
5.11.3.3 Asia-Pacific  
5.11.4 Impact on End-use Industries  
5.11.4.1 Pharmaceutical & Biotech Companies  
5.11.4.2 Healthcare Providers & Clinicians  
5.11.4.3 Other End-users  
  
**6 Technological Advancements, AI-Driven Impact, Patents, Innovations, and Future Applications**  
6.1 Key Technologies  
6.1.1 Advanced Biosensing and Multi-Parameter Wearables  
6.1.2 AI-Driven Analytics and Clinical Intelligence  
6.2 Complementary Technologies  
6.2.1 Mobile Health and Remote Patient Monitoring  
6.2.2 Analytics and Population-Level Health Data Integration  
6.3 Adjacent Technologies  
6.3.1 Internet of Medical Things and Connected Devices  
6.3.2 Cloud and Edge Computing  
6.4 Technology/Product Roadmap  
6.5 Patent Analysis  
6.5.1 Patent Publication Trends  
6.5.2 Jurisdiction and Top Applicant Analysis  
6.6 Future Applications  
6.6.1 AI-Driven Predictive Monitoring and Clinical Decision Support  
6.6.2 Closed-Loop Therapeutic and Drug Delivery Systems  
6.6.3 Decentralized and Hybrid Clinical Trial Enablement  
6.6.4 Continuous Disease Management and Preventive Healthcare  
6.6.5 Advanced Biosensing and Non-Invasive Diagnostics  
6.6.6 Integration with Digital Therapeutics and Personalized Medicine  
6.7 Impact of AI/Gen AI  
6.7.1 Market Potential of AI/Gen AI  
6.7.2 Case Studies Related to AI/Gen AI Implementation  
6.7.2.1 AI-Driven Continuous Glucose Monitoring and Diabetes Management at Dexcom  
6.7.3 Impact of AI/Gen AI on Interconnected and Adjacent Ecosystems  
6.7.3.1 Wearable Data Analytics and AI-Driven Monitoring Platforms  
6.7.3.2 Digital Health Platforms, Integration, and Regulatory Infrastructure  
6.7.3.3 Clinical Care, Remote Monitoring, and Personalized Therapeutics  
6.7.4 User Readiness and Impact Assessment  
6.7.4.1 User Readiness  
6.7.4.1.1 User A: Hospitals, Clinics, and Long-Term Care Providers  
6.7.4.1.2 User B: Pharma and Biotech Companies  
6.7.4.2 Impact Assessment  
6.7.4.2.1 User A: Hospitals, Clinics, and Long-Term Care Providers  
6.7.4.2.1.1 Implementation  
6.7.4.2.1.2 Impact  
6.7.4.2.2 User B: Pharma and Biotech Companies  
6.7.4.2.2.1 Implementation  
6.7.4.2.2.2 Impact  
  
**7 Regulatory Landscape**  
7.1 Regional Regulations and Compliance  
7.1.1 Regulatory Bodies, Government Agencies, and Other Organizations  
7.1.2 Industry Standards  
  
**8 Customer Landscape and Buyer Behavior**  
8.1 Decision-Making Process  
8.2 Key Stakeholders in Buying Process and Their Evaluation Criteria  
8.2.1 Key Stakeholders Involved in Buying Process  
8.2.2 Buying Criteria  
8.3 Adoption Barriers and Internal Challenges  
8.4 Unmet Needs from End-use Industries  
8.4.1 Unmet Needs  
8.4.2 End-user Expectations  
8.5 Market Profitability  
  
**9 Wearables in Pharma & Biotech Market, by Product**  
9.1 Introduction  
9.2 Smartwatches  
9.2.1 Expanding Role in Digital Clinical Trials and Remote Monitoring  
9.3 Fitness Bands  
9.3.1 Emphasis on Real-World Evidence and Patient-Centric Trial Designs  
9.4 Smart Rings  
9.4.1 Emerging Clinical-Grade Wearables Enabling Early Disease Detection and Continuous Monitoring  
9.5 Continuous Glucose Monitors  
9.5.1 Transforming Metabolic Research Through Real-Time, High-Frequency Data  
9.6 Patches  
9.6.1 Continuous, Clinical-Grade Monitoring Driving Adoption in Decentralized Trials  
9.7 Wearable Injectors  
9.7.1 Growing Demand for Self-Administration of Biologics in Chronic Disease Management  
9.8 Other Products  
  
**10 Wearables in Pharma & Biotech Market, by Therapeutic Area**  
10.1 Introduction  
10.2 Cardiovascular  
10.2.1 Atherosclerotic Cardiovascular Diseases/Secondary Prevention  
10.2.1.1 Focus on Improving Endpoint Capture and Long-Term Outcomes Monitoring  
10.2.2 Heart Failure  
10.2.2.1 Continuous Physiologic Monitoring and AI-Enabled Decompensation Prediction  
10.2.3 Hypertension  
10.2.3.1 Cuffless Monitoring and AI-Driven Adherence Management Enabling Precision Blood Pressure Control  
10.2.4 Atrial Fibrillation/Stroke Prevention  
10.2.4.1 Rapid Expansion of AI-Powered Arrhythmia Detection Algorithms and Regulatory-Cleared Wearable ECG Technologies  
10.2.5 Pulmonary Hypertension  
10.2.5.1 Growing Use of Wearable-Enabled Remote Monitoring and AI Analytics to Generate Objective, Real-World Functional Endpoints  
10.2.6 Structural Heart Diseases/Interventional Cardiology  
10.2.6.1 Wearable-Enabled Remote Recovery Monitoring and Procedural Optimization Supporting Precision Structural Heart Care  
10.3 Oncology  
10.3.1 Solid Tumors  
10.3.1.1 Breast Cancer  
10.3.1.1.1 Continuous Wearable-based Survivorship Monitoring and Decentralized Oncology Trials Driving Personalized Long-Term Care Models  
10.3.1.2 Lung Cancer  
10.3.1.2.1 Constant Respiratory Monitoring and Decentralized Trial Adoption  
10.3.1.3 Prostate Cancer  
10.3.1.3.1 Expansion of Decentralized Oncology Trials and Long-Term Survivorship Management  
10.3.1.4 Colorectal Cancer  
10.3.1.4.1 Increasing Adoption of Decentralized Oncology Trials and Remote Post-Surgical Monitoring  
10.3.1.5 Brain Tumor  
10.3.1.5.1 Remote Neurologic Surveillance and Functional Recovery Tracking Accelerating Personalized Care  
10.3.1.6 Other Solid Tumors  
10.3.2 Hematologic Malignancies  
10.3.2.1 Leukemia  
10.3.2.1.1 Wearable-Enabled Infection Surveillance and Treatment Resilience Monitoring Transforming Outpatient Care  
10.3.2.2 Lymphoma  
10.3.2.2.1 Shift Toward Outpatient Infusion Centers, Home-based Recovery, and Decentralized Clinical Trials  
10.3.2.3 Multiple Myeloma  
10.3.2.3.1 Real-Time Toxicity and Mobility Tracking Using Wearables in Long-Term Management  
10.3.2.4 Other Hematologic Malignancies  
10.3.3 Diabetes  
10.3.3.1 Critical Need for Long-Term, Real-World Metabolic Monitoring  
10.3.4 Mental Health & Behavioral Health  
10.3.4.1 Rising Global Burden of Psychiatric Disorders  
10.3.5 Respiratory Disorders  
10.3.5.1 Early Exacerbation Detection Through Continuous Monitoring Reduces Hospitalization  
10.3.6 Lifestyle & Wellness Improvement  
10.3.6.1 Continuous Tracking for Lifestyle Optimization and Preventive Health Risk Management  
10.3.7 Neurology  
10.3.7.1 Wearable-based Monitoring of Neurological Function and Digital Clinical Endpoints in Cns Disorders  
10.3.8 Musculoskeletal Disorders/Pain Management  
10.3.8.1 Wearable-Guided Functional Movement and Chronic Pain Monitoring in Musculoskeletal Disorders  
10.3.9 Women's Health & Reproductive Health  
10.3.9.1 Continuous Physiological and Reproductive Cycle Using Wearables  
10.3.10 Other Diseases  
  
**11 Wearables in Pharma & Biotech Market, by Application**  
11.1 Introduction  
11.2 Drug Discovery  
11.2.1 Recent Advances Promote Discovery of Drugs Through Wearables in Pharma & Biotech  
11.3 Clinical Trials  
11.3.1 Phase II  
11.3.1.1 AI-Enabled Remote Monitoring and Adaptive Trial Designs Accelerate Adoption  
11.3.2 Phase III  
11.3.2.1 Rapid Expansion of Decentralized and Hybrid Global Trial Models Propels Growth  
11.3.3 Phase IV  
11.3.3.1 Ability to Improve Patient Engagement and Retention in Long-Duration Studies Drives Market  
11.4 Medication Adherence & Behavioral Support  
11.4.1 Connected Reminders, Passive Monitoring, and Personalized Nudges Boost Adoption  
11.5 Chronic Disease Monitoring  
11.5.1 Continuous Physiological Tracking and Proactive Intervention Capabilities Increase Adoption  
11.6 Personalized & Preventive Digital Therapeutics  
11.6.1 Biometric Sensing and AI-Driven Coaching Raise Demand for Wearables  
  
**12 Wearables in Pharma & Biotech Market, by End-user**  
12.1 Introduction  
12.2 Pharmaceutical & Biotech Companies  
12.2.1 Clinical Digitization, Real-World Evidence Generation, and Connected Therapy Models Drive Market  
12.3 Healthcare Providers & Clinicians  
12.3.1 Remote Patient Monitoring, Preventive Care, and Data-Driven Clinical Decision Support Boost Growth  
12.4 Contract Research Organizations  
12.4.1 Decentralized Trials, Wearable Data Integration, and Faster Clinical Execution Raise Demand  
12.5 Other End-users  
  
**13 Wearables in Pharma & Biotech Market, by Region**  
13.1 Introduction  
13.2 North America  
13.2.1 US  
13.2.1.1 High Concentration of Clinical Research Activity, Clinical Trial Inefficiencies, and Cost Pressures to Drive Market  
13.2.2 Canada  
13.2.2.1 Clinical Research Participation, Public Health Burden, and Digital Health Adoption to Drive Market  
13.3 Europe  
13.3.1 Germany  
13.3.1.1 Expanding Clinical Trial Activity and Regulatory Leadership to Drive Market  
13.3.2 France  
13.3.2.1 Regulatory-First Approach to Healthcare and Clinical Innovation to Drive Market  
13.3.3 Uk  
13.3.3.1 Real-World Data Integration and Decentralized Trial Innovation to Drive Market  
13.3.4 Italy  
13.3.4.1 Evolving Clinical Trial Landscape and Regulatory Decentralization to Drive Market  
13.3.5 Spain  
13.3.5.1 Increasing Investment in Digital Health Infrastructure to Drive Market  
13.3.6 Rest of Europe  
13.4 Asia-Pacific  
13.4.1 China  
13.4.1.1 Clinical Trial Expansion and Real-World Data Integration to Drive Market  
13.4.2 Japan  
13.4.2.1 Late-Stage Trial Leadership and Regulatory Precision to Drive Market  
13.4.3 India  
13.4.3.1 High-Volume Phase III Trial Ecosystem and Abdm-Driven Digital Health Integration to Drive Market  
13.4.4 Australia  
13.4.4.1 Early-Phase Trial Leadership and Remote Care Needs to Drive Market  
13.4.5 South Korea  
13.4.5.1 Integrated Clinical Trial Ecosystem and National Health Data Infrastructure to Drive Market  
13.4.6 Rest of Asia-Pacific  
13.5 Latin America  
13.5.1 Brazil  
13.5.1.1 Clinical Trial Leadership and High Diabetes Burden to Drive Market  
13.5.2 Mexico  
13.5.2.1 Regulatory Reforms and Phase III Trial Expansion to Drive Market  
13.5.3 Rest of Latin America  
13.6 Middle East & Africa  
13.6.1 Gcc  
13.6.2 Saudi Arabia  
13.6.2.1 Vision 2030-Led Digital Health Transformation to Drive Market  
13.6.3 Uae  
13.6.3.1 Digital Health Strategy, Clinical Trial Expansion, and High Healthcare Investment to Drive Market  
13.6.4 Rest of Gcc  
13.6.5 South Africa  
13.6.5.1 Clinical Trial Leadership and Decentralized Care Models to Drive Market  
13.6.6 Rest of Middle East & Africa  
  
**14 Competitive Landscape**  
14.1 Overview  
14.2 Key Player Strategies/Right to Win, 2023-2026  
14.3 Revenue Analysis, 2021-2025  
14.4 Market Share Analysis, 2025  
14.5 Brand/Product Comparison  
14.6 Company Valuation and Financial Metrics  
14.7 Company Evaluation Matrix: Key Players, 2025  
14.7.1 Stars  
14.7.2 Emerging Leaders  
14.7.3 Pervasive Players  
14.7.4 Participants  
14.7.5 Company Footprint: Key Players, 2025  
14.7.5.1 Company Footprint  
14.7.5.2 Region Footprint  
14.7.5.3 Product Footprint  
14.7.5.4 Therapeutic Area Footprint  
14.7.5.5 Application Footprint  
14.7.5.6 End-user Footprint  
14.8 Company Evaluation Matrix: Start-Ups/SMEs, 2025  
14.8.1 Progressive Companies  
14.8.2 Responsive Companies  
14.8.3 Dynamic Companies  
14.8.4 Starting Blocks  
14.8.5 Competitive Benchmarking: Start-Ups/SMEs, 2025  
14.8.5.1 List of Start-Ups/SMEs  
14.8.5.2 Competitive Benchmarking of Start-Ups/SMEs  
14.9 Competitive Scenario  
14.9.1 Product Launches and Approvals  
14.9.2 Deals  
14.9.3 Other Developments  
  
**15 Company Profiles**  
15.1 Key Players  
15.1.1 Dexcom, Inc.  
15.1.1.1 Business Overview  
15.1.1.2 Products Offered  
15.1.1.3 Recent Developments  
15.1.1.3.1 Product Launches and Approvals  
15.1.1.3.2 Deals  
15.1.1.4 Analyst's View  
15.1.1.4.1 Right to Win  
15.1.1.4.2 Strategic Choices  
15.1.1.4.3 Weaknesses and Competitive Threats  
15.1.2 Abbott  
15.1.2.1 Business Overview  
15.1.2.2 Products Offered  
15.1.2.3 Recent Developments  
15.1.2.3.1 Product Launches and Approvals  
15.1.2.3.2 Deals  
15.1.2.3.3 Other Developments  
15.1.2.4 Analyst's View  
15.1.2.4.1 Right to Win  
15.1.2.4.2 Strategic Choices  
15.1.2.4.3 Weaknesses and Competitive Threats  
15.1.3 Masimo  
15.1.3.1 Business Overview  
15.1.3.2 Products Offered  
15.1.3.3 Recent Developments  
15.1.3.3.1 Product Launches and Approvals  
15.1.3.3.2 Deals  
15.1.3.4 Analyst's View  
15.1.3.4.1 Right to Win  
15.1.3.4.2 Strategic Choices  
15.1.3.4.3 Weaknesses and Competitive Threats  
15.1.4 Bd  
15.1.4.1 Business Overview  
15.1.4.2 Products Offered  
15.1.4.3 Recent Developments  
15.1.4.3.1 Product Launches and Approvals  
15.1.4.3.2 Deals  
15.1.4.4 Analyst's View  
15.1.4.4.1 Right to Win  
15.1.4.4.2 Strategic Choices  
15.1.4.4.3 Weaknesses and Competitive Threats  
15.1.5 Apple Inc.  
15.1.5.1 Business Overview  
15.1.5.2 Products Offered  
15.1.5.3 Recent Developments  
15.1.5.3.1 Product Launches and Approvals  
15.1.5.3.2 Deals  
15.1.5.4 Analyst's View  
15.1.5.4.1 Right to Win  
15.1.5.4.2 Strategic Choices  
15.1.5.4.3 Weaknesses and Competitive Threats  
15.1.6 Boston Scientific Corporation  
15.1.6.1 Business Overview  
15.1.6.2 Products Offered  
15.1.6.3 Recent Developments  
15.1.6.3.1 Deals  
15.1.7 Irhythm Technologies, Inc.  
15.1.7.1 Business Overview  
15.1.7.2 Products Offered  
15.1.7.3 Recent Developments  
15.1.7.3.1 Product Launches and Approvals  
15.1.7.3.2 Deals  
15.1.8 Koninklijke Philips N.V.  
15.1.8.1 Business Overview  
15.1.8.2 Products Offered  
15.1.8.3 Recent Developments  
15.1.8.3.1 Product Launches and Approvals  
15.1.8.3.2 Deals  
15.1.8.3.3 Other Developments  
15.1.9 Medtronic  
15.1.9.1 Business Overview  
15.1.9.2 Products Offered  
15.1.9.3 Recent Developments  
15.1.9.3.1 Deals  
15.1.10 Biointellisense, Inc.  
15.1.10.1 Business Overview  
15.1.10.2 Products Offered  
15.1.10.3 Recent Developments  
15.1.10.3.1 Product Launches and Approvals  
15.1.10.3.2 Deals  
15.1.11 F. Hoffmann-La Roche Ltd.  
15.1.11.1 Business Overview  
15.1.11.2 Products Offered  
15.1.11.3 Recent Developments  
15.1.11.3.1 Product Launches and Approvals  
15.1.12 GE Healthcare  
15.1.12.1 Business Overview  
15.1.12.2 Products Offered  
15.1.12.3 Recent Developments  
15.1.12.3.1 Product Launches and Approvals  
15.1.12.3.2 Deals  
15.1.13 Biobeat  
15.1.13.1 Business Overview  
15.1.13.2 Products Offered  
15.1.13.3 Recent Developments  
15.1.13.3.1 Product Launches and Approvals  
15.1.13.3.2 Deals  
15.1.13.3.3 Other Developments  
15.1.14 Empatica Inc.  
15.1.14.1 Business Overview  
15.1.14.2 Products Offered  
15.1.14.3 Recent Developments  
15.1.14.3.1 Product Launches and Approvals  
15.1.14.3.2 Deals  
15.1.15 Vitalconnect  
15.1.15.1 Business Overview  
15.1.15.2 Products Offered  
15.1.15.3 Recent Developments  
15.1.15.3.1 Deals  
15.1.15.3.2 Other Developments  
15.1.16 Ametris, LLC  
15.1.16.1 Business Overview  
15.1.16.2 Products Offered  
15.1.16.3 Recent Developments  
15.1.16.3.1 Deals  
15.1.17 Alivecor, Inc.  
15.1.17.1 Business Overview  
15.1.17.2 Products Offered  
15.1.17.3 Recent Developments  
15.1.17.3.1 Product Launches and Approvals  
15.1.17.3.2 Deals  
15.1.18 Withings  
15.1.18.1 Business Overview  
15.1.18.2 Products Offered  
15.1.18.3 Recent Developments  
15.1.18.3.1 Product Launches and Approvals  
15.1.18.3.2 Deals  
15.1.19 Vivalnk, Inc.  
15.1.19.1 Business Overview  
15.1.19.2 Products Offered  
15.1.19.3 Recent Developments  
15.1.19.3.1 Product Launches and Approvals  
15.1.20 Medibiosense  
15.1.20.1 Business Overview  
15.1.20.2 Products Offered  
15.1.20.3 Recent Developments  
15.1.20.3.1 Product Launches and Approvals  
15.2 Other Players  
15.2.1 Sibel Health, Inc.  
15.2.2 Byteflies  
15.2.3 Strados Labs  
15.2.4 Onera Technologies B.V.  
15.2.5 Epicore Biosystems, Inc.  
  
**16 Research Methodology**  
16.1 Research Approach  
16.1.1 Secondary Research  
16.1.1.1 Key Data from Secondary Sources  
16.1.2 Primary Research  
16.1.2.1 Primary Sources  
16.1.2.2 Key Data from Primary Sources  
16.1.2.3 Breakdown of Primary Interviews  
16.1.2.4 Insights from Primary Experts  
16.2 Research Methodology Design  
16.3 Market Size Estimation  
16.4 Data Triangulation  
16.5 Research Assumptions  
16.6 Research Limitations  
16.6.1 Methodology-Related  
16.6.2 Scope-Related  
16.7 Risk Assessment  
  
**17 Appendix**  
17.1 Discussion Guide  
17.2 Knowledgestore: The Subscription Portal  
17.3 Customization Options  
  
**List of Tables \[468\]**  
**List of Figures \[46\]**  
  
**Companies Featured**

-   Dexcom, Inc.
-   Abbott
-   Masimo
-   Bd
-   Apple Inc.
-   Boston Scientific Corporation
-   Irhythm Technologies, Inc.
-   Koninklijke Philips N.V.
-   Medtronic
-   Biointellisense, Inc.
-   F. Hoffmann-La Roche Ltd.
-   GE Healthcare
-   Biobeat
-   Empatica Inc.
-   Vitalconnect
-   Ametris, LLC
-   Alivecor, Inc.
-   Withings
-   Vivalnk, Inc.
-   Medibiosense
-   Sibel Health, Inc.
-   Byteflies
-   Strados Labs
-   Onera Technologies B.V.
-   Epicore Biosystems, Inc.

For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6234836/wearables-in-pharma-and-biotech-market-product?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=jtfgzt&amp;utm_campaign=2404926+-+Global+Wearables+in+Pharma+%26+Biotech+Market+by+Product%2c+Therapy%2c+Application%2c+and+End+User+-+Forecast+to+2031+%7c+AI+and+Remote+Monitoring+Drive+20.2%25+CAGR+to+%249.97+Billion&amp;utm_exec=clshmsai" rel="nofollow">https://www.researchandmarkets.com/r/90u94n</a>

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 

  
![](https://ml.globenewswire.com/media/YmJjN2MwNDItOWI2Zi00NjMwLTkyZmUtMTBkYWNkZjFjZjJlLTEwMjY3MzctMjAyNi0xMS0xNy1lbg==/tiny/Research-and-Markets.png)

## Related

- [Global Medical Robots Market Size, Share, Growth Analysis, and Forecast 2026-2035 | AI-Enabled Surgery and Automation Propel 22.20% CAGR Toward USD 141.15 Billion](https://healthcarenews.io/news/global-medical-robots-market-size-share-growth-analysis-and-forecast-2026-2035-ai-enabled.md)
- [Peripheral Nerve Stimulators Market Size, Share, Trends, and Forecast, 2026-2033 | Market to Reach USD 898.1 Million as Wireless Systems and Outpatient Care Drive 14.3% CAGR](https://healthcarenews.io/news/peripheral-nerve-stimulators-market-size-share-trends-and-forecast-2026-2033-market-to-rea.md)
- [Single-cell Proteomics Market Size, Share, Trends, and Forecast, 2026-2033 | Market to Reach USD 2.01 Billion as Precision Medicine and Drug Discovery Fuel 14.0% CAGR](https://healthcarenews.io/news/single-cell-proteomics-market-size-share-trends-and-forecast-2026-2033-market-to-reach-usd.md)
- [Global Healthcare Analytics Market Size, Share, Trends, and Forecast, 2026-2033 | AI and Cloud Adoption to Drive 13.5% CAGR, Creating a USD 198.8 Billion Market](https://healthcarenews.io/news/global-healthcare-analytics-market-size-share-trends-and-forecast-2026-2033-ai-and-cloud-a.md)
